Premium
A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle
Author(s) -
O'Neill Paul M.,
Ward Stephen A.
Publication year - 2015
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201507264
Subject(s) - malaria , parasite hosting , drug discovery , plasmodium (life cycle) , drug , pharmacology , chloroquine , quinoline , biology , phenotypic screening , computational biology , virology , medicine , immunology , bioinformatics , phenotype , chemistry , genetics , computer science , gene , organic chemistry , world wide web
Putting a stop to malaria : Phenotypic screening against malaria parasites, hit identification, and efficient lead optimization have delivered the preclinical candidate antimalarial DDD107498. This molecule is distinctive in that it has potential for use as a single‐dose cure for malaria and shows a unique broad spectrum of activity against the liver, blood, and mosquito stages of the parasite life cycle.